Abstract

Response rate, toxicity, and survival in fit, elderly NSCLC patients receiving platinum-based treatment appear to be similar to those in younger patients, although patients 70 years old or older have more comorbidities and can expect more leukopenia and neuropsychiatric toxicity. Advanced age alone should not preclude appropriate NSCLC treatment.

Keywords

MedicineInternal medicineLung cancerEtoposideLeukopeniaPerformance statusChemotherapyRandomized controlled trialLog-rank testExact testCisplatinOncologySurvival analysisSurgery

Affiliated Institutions

Related Publications

Comparison of Survival and Quality of Life in Advanced Non–Small-Cell Lung Cancer Patients Treated With Two Dose Levels of Paclitaxel Combined With Cisplatin Versus Etoposide With Cisplatin: Results of an Eastern Cooperative Oncology Group Trial

Philip Bonomi , KyungMann Kim , Diane L. Fairclough +5 more

PURPOSE: Treatment with cisplatin-based chemotherapy provides a modest survival advantage over supportive care alone in advanced non–small-cell lung cancer (NSCLC). To determine...

2000 Journal of Clinical Oncology 593 citations

Publication Info

Year
2002
Type
article
Volume
94
Issue
3
Pages
173-181
Citations
507
Access
Closed

External Links

View on DOI.org

Social Impact

Altmetric
PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

507
OpenAlex

Cite This

Corey J. Langer, Judith Manola, Patricia Bernardo et al. (2002). Cisplatin-Based Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: Implications of Eastern Cooperative Oncology Group 5592, a Randomized Trial. JNCI Journal of the National Cancer Institute , 94 (3) , 173-181. https://doi.org/10.1093/jnci/94.3.173

Identifiers

DOI
10.1093/jnci/94.3.173